The Food and Drug Administration (FDA) this week approved Caplyta (lumateperone), an oral atypical a...
While connecting individuals with first-episode psychosis (FEP) to coordinated specialty care is kno...
MIN-101—a novel compound that binds to sigma-2 and 5-HT2A receptors—appears to reduce negative sympt...
Despite the fact that early nonresponse to antipsychotic therapy in patients with schizophrenia is k...
